Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction.

CONTEXT Fetal growth restriction (FGR) is a leading cause of perinatal mortality, yet no reliable screening test exists. Placental specific mRNA in the maternal circulation may reflect changes in the placental transcriptome in FGR and could be a novel biomarker for FGR. OBJECTIVE The aim of the study was to identify placental specific RNA detectable in the maternal circulation and examine whether they are differentially expressed in severe preterm FGR. DESIGN In silico screening was used to identify placental specific RNAs. Their expression in cases of severe FGR vs controls was examined in both maternal blood and placenta by microarray, RT-PCR, and in situ hybridization. RESULTS Via in silico analysis, we identified 137 genes very highly expressed in the placenta relative to other tissues. Using microarray, we found that they were detectable in the maternal blood and were globally dysregulated with preterm FGR; 75 genes (55%) had a ≥1.5-fold differential expression compared to controls. Eight genes (ERVWE-1, PSG1, PLAC4, TAC3, PLAC3, CRH, CSH1, and KISS1) were validated by RT-PCR to be significantly increased in both maternal blood and placenta in a larger cohort of severe FGR compared to controls. In situ hybridization confirmed PAPPA2 and ERVWE-1 localized to the syncytiotrophoblast. CONCLUSION There is global differential expression of placental specific mRNA in the maternal blood in pregnancies complicated by severe preterm FGR. Placental specific mRNA in maternal blood may represent a new class of biomarkers for preterm FGR.

[1]  P. Baker,et al.  Placental apoptosis in normal human pregnancy. , 1997, American journal of obstetrics and gynecology.

[2]  S. Gardiner,et al.  Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia , 2000, Nature.

[3]  Gordon C. S. Smith,et al.  Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. , 2002, The Journal of clinical endocrinology and metabolism.

[4]  I. Sargent,et al.  Presence of fetal DNA in maternal plasma and serum , 1997, The Lancet.

[5]  R. Schild,et al.  Microarray analysis of placental tissue in intrauterine growth restriction , 2010, Clinical endocrinology.

[6]  Charles R Cantor,et al.  Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection , 2007, Nature Medicine.

[7]  D. Spandidos,et al.  Angiogenic factors in placentas from pregnancies complicated by fetal growth restriction (review). , 2012, Molecular medicine reports.

[8]  L. Poon,et al.  Presence of fetal RNA in maternal plasma. , 2000, Clinical chemistry.

[9]  K. C. Chan,et al.  Systematic micro-array based identification of placental mRNA in maternal plasma: towards non-invasive prenatal gene expression profiling , 2004, Journal of Medical Genetics.

[10]  M. Vidaud,et al.  Direct Involvement of HERV-W Env Glycoprotein in Human Trophoblast Cell Fusion and Differentiation , 2003, Molecular and Cellular Biology.

[11]  Y. B. Gordon,et al.  CIRCULATING LEVELS OF PREGNANCY‐SPECIFIC β1−GLYCOPROTEIN AND HUMAN PLACENTAL LACTOGEN IN THE THIRD TRIMESTER OF PREGNANCY: THEIR RELATIONSHIP TO PARITY, BIRTH WEIGHT, AND PLACENTAL WEIGHT , 1977, British journal of obstetrics and gynaecology.

[12]  M. Beckmann,et al.  Impaired cell fusion and differentiation in placentae from patients with intrauterine growth restriction correlate with reduced levels of HERV envelope genes , 2010, Journal of Molecular Medicine.

[13]  M. Epstein,et al.  PREINVASIVE CANCER OF THE CERVIX. , 1964, Lancet.

[14]  M. Ounsted,et al.  Perinatal morbidity and mortality in small-for-dates babies: the relative importance of some maternal factors. , 1981, Early human development.

[15]  C. Whitehead,et al.  Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia. , 2011, The Journal of clinical endocrinology and metabolism.

[16]  R. Baxter,et al.  Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. , 2010, The Journal of clinical endocrinology and metabolism.

[17]  Majid Ezzati,et al.  Stillbirths: the way forward in high-income countries , 2011, The Lancet.

[18]  Q. Qiu,et al.  Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse. , 2009, The Journal of endocrinology.

[19]  B. Stray-Pedersen,et al.  Restricted fetal growth in sudden intrauterine unexplained death , 2004, Acta obstetricia et gynecologica Scandinavica.

[20]  M. Laan,et al.  Differential expression profile of growth hormone/chorionic somatomammotropin genes in placenta of small- and large-for-gestational-age newborns. , 2010, The Journal of clinical endocrinology and metabolism.

[21]  W. B. Robertson,et al.  FETAL GROWTH RETARDATION AND THE ARTERIES OF THE PLACENTAL BED , 1977, British journal of obstetrics and gynaecology.

[22]  K. Maršál,et al.  Obstetric management of intrauterine growth restriction. , 2009, Best practice & research. Clinical obstetrics & gynaecology.

[23]  R. Reynolds,et al.  Decreased serum levels of kisspeptin in early pregnancy are associated with intra‐uterine growth restriction and pre‐eclampsia , 2009, Prenatal diagnosis.

[24]  S. Karumanchi,et al.  Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2012, Hypertension.

[25]  C. Oudejans,et al.  Non-invasive aneuploidy detection using free fetal DNA and RNA in maternal plasma: recent progress and future possibilities. , 2011, Human reproduction update.

[26]  D. Sahota,et al.  A strategy for identifying circulating placental RNA markers for fetal growth assessment , 2009, Prenatal diagnosis.

[27]  Eva M. L. Smets,et al.  Decreased plasma levels of metastin in early pregnancy are associated with small for gestational age neonates , 2008, Prenatal diagnosis.

[28]  A. Davenport,et al.  Kisspeptins are novel potent vasoconstrictors in humans, with a discrete localization of their receptor, G protein-coupled receptor 54, to atherosclerosis-prone vessels. , 2007, Endocrinology.

[29]  A. Chicz–DeMet,et al.  Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. , 2004, American journal of obstetrics and gynecology.

[30]  A. Baschat.  Fetal growth restriction – from observation to intervention , 2010, Journal of perinatal medicine.

[31]  Mark R. Johnson,et al.  Phenotype and mRNA Expression of Syncytiotrophoblast Microparticles Isolated from Human Placenta , 2008, Annals of the New York Academy of Sciences.